We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

157 hedge funds and large institutions have $100M invested in Coherus Oncology in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 10

37% more capital invested

Capital invested by funds: $72.8M → $100M (+$27.2M)

24% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 37

24% more funds holding

Funds holding: 127 → 157 (+30)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.91% less ownership

Funds ownership: 42.46% → 39.54% (-2.9%)

70% less call options, than puts

Call options by funds: $132K | Put options by funds: $436K

Holders
157
Holders Change
+30
Holders Change %
+23.62%
% of All Funds
1.93%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
42
Increased
46
Reduced
37
Closed
10
Calls
$132K
Puts
$436K
Net Calls
-$304K
Net Calls Change
-$804K

Top Buyers

1
SB
Samsara BioCapital
California
+$6.09M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$4M
3
Two Sigma Investments
Two Sigma Investments
New York
+$3.19M
4
PBM
Propel Bio Management
California
+$2.52M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.54M

Top Sellers

1
TCM
Tang Capital Management
California
-$1.49M
2
Jane Street
Jane Street
New York
-$1,000K
3
Millennium Management
Millennium Management
New York
-$619K
4
BlackRock
BlackRock
New York
-$351K
5
PAM
Panagora Asset Management
Massachusetts
-$286K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWA
126
EverSource Wealth Advisors
Alabama
$6.05K +$1.96K +1,101 +44%
Royal Bank of Canada
127
Royal Bank of Canada
Ontario, Canada
$5K -$3.54K -1,995 -39%
GFM
128
GF Fund Management
China
$4.59K +$733 +413 +18%
SCM
129
Sterling Capital Management
North Carolina
$4.39K -$3.12K -1,758 -40%
CA
130
CoreCap Advisors
Michigan
$4.18K +$4.39K +2,472 New
FFA
131
Farther Finance Advisors
California
$3.71K +$218 +123 +6%
EP
132
Essential Partners
California
$2.61K +$1.58K +892 +137%
Osaic Holdings
133
Osaic Holdings
Arizona
$2.6K -$243 -137 -8%
Optiver Holding
134
Optiver Holding
Netherlands
$2.31K -$6.71K -3,777 -73%
SC
135
Swan Capital
Florida
$2.2K – – –
GI
136
GAMMA Investing
California
$2.04K +$1.43K +803 +197%
SGK
137
Steigerwald Gordon & Koch
Virginia
$1.69K – – –
AF
138
Allworth Financial
California
$1.43K +$1.39K +784 +1,265%
SS
139
SBI Securities
Japan
$1.16K -$62 -35 -5%
OCWP
140
Owl Creek Wealth Partners
Colorado
$1.16K +$1.22K +684 New
IA
141
IFP Advisors
Florida
$1.03K -$121 -68 -10%
AW
142
Avion Wealth
Texas
$1K – – –
Nisa Investment Advisors
143
Nisa Investment Advisors
Missouri
$970 – – –
CCWM
144
Cassaday & Co Wealth Management
Virginia
$643 +$675 +380 New
TWD
145
True Wealth Design
Ohio
$575 +$78 +44 +15%
Rockefeller Capital Management
146
Rockefeller Capital Management
New York
$548 – – –
CA
147
Clearstead Advisors
Ohio
$449 -$5 -3 -1%
AAP
148
Arax Advisory Partners
Colorado
$394 +$375 +211 +959%
SIS
149
Sound Income Strategies
Florida
$348 – – –
RFP
150
Root Financial Partners
California
$336 +$353 +199 New
3 4 5
6
7

CHRS Hedge Fund Activity: Q1 2026 in Review

157 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2026, worth a combined $100M — up 37% from $72.8M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new CHRS positions and 10 closed out — a net gain of 32 holders — while 46 added to existing stakes and 37 trimmed.

The largest buyer was Samsara BioCapital, opening a new position worth an estimated $6.09M. The largest seller was Tang Capital Management, cutting an estimated $1.49M.

  • 157 institutional investors held Coherus Oncology (CHRS) as of Q1 2026, up from 127 in Q4 2025.
  • Funds reported $100M of Coherus Oncology stock for Q1 2026, up 37% quarter-over-quarter.
  • 42 funds opened new Coherus Oncology positions in Q1 2026 and 10 closed out, a net change of +32 holders.
  • The largest Coherus Oncology buyer in Q1 2026 was Samsara BioCapital, an estimated $6.09M added.
  • The largest Coherus Oncology seller in Q1 2026 was Tang Capital Management, an estimated $1.49M sold.

Based on aggregated 13F filings for Q1 2026.